MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type

Several randomized trials have demonstrated non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations can achieve favorable clinical outcomes on treatment with EGFR tyrosine kinase inhibitors (TKIs). EGFR mutation is considered as a predictive mark...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Li, Jiayu, Li, Xuefei, Ren, Shengxiang, Chen, Xiaoxia, Zhang, Yishi, Zhou, Fei, Zhao, Mingchuan, Zhao, Chao, Chen, Xiu, Cheng, Ningning, Zhao, Yinmin, Zhou, Caicun, Hirsch, Fred R.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2014
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4202169/
https://ncbi.nlm.nih.gov/pubmed/25277203
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky